Write the Friday-lift claim first
Someone will tell you the capsule 'kicked in' after two good nights. Write that down. Then open section 14.
The prescribing information is blunt about timing. As with other drugs for major depression, the full effect may be delayed. For obsessive-compulsive disorder the same label says the full therapeutic effect may wait until five weeks or longer. That is not a counseling slogan invented on this desk. It is how the trials were built. Five- and six-week depression studies. Thirteen-week OCD studies. If your review clock is a weekend, you are scoring a different object than the FDA scored.
Placebo response in depression is large. A meaningful share of people improve on a dummy pill, so the extra gain on fluoxetine is real and also smaller than raw 'it helped me' stories imply. Strike two false exits at once: 'it does nothing' and 'it should have fixed Friday.' The honest middle is incremental, slow, and worth the wait where the indication is strong. Mechanism and half-life that explain the lag sit in the Prozac 20 mg fact line.
HAM-D in the adult depression rooms
Adult efficacy was studied in five- and six-week placebo-controlled trials of depressed outpatients whose diagnoses mapped to major depressive disorder. Fluoxetine beat placebo on the Hamilton Depression Rating Scale. It also beat placebo on HAM-D pieces the label bothers to name: depressed mood, sleep disturbance, and the anxiety subfactor. Those are scale points, not vibes. They are also short rooms. Six weeks is long if you are the patient. It is brief if you expected a personality rewrite.
Response in later analyses often means a 50 percent drop on HAM-D. Remission is tighter - the elderly 20 mg pair used a total endpoint HAM-D of 8 or less. Averages hide people who move a lot and people who barely move. A first SSRI helping a good fraction, doing little for others, and sometimes needing a switch is the ordinary pattern, not a Prozac-specific failure. Comparability with older antidepressants, not superiority, is the accurate adult read.
Twenty milligrams in the over-60 studies
Two six-week controlled studies randomized 671 older outpatients to Prozac 20 mg or placebo.
Those rooms matter because this site's SERP lock is 20 mg, and the label still treats 20 mg daily as enough for many adults with major depression. In patients 60 and older, 20 mg produced a higher rate of response and of remission than placebo. Discontinuations for adverse reactions were 12 percent on drug and 9 percent on placebo - close enough that 'the elderly cannot tolerate it' does not survive the table.
Do not inflate that into '20 mg is the only dose anyone needs.' The adult depression range on the label runs 20 to 80 mg. The point of the elderly pair is narrower: the same capsule strength this file keeps naming already had randomized backing in a group people often assume needs a special start. If someone is shopping 'Prozac 20 mg reviews' and wants a number instead of a vibe, this is one of the cleaner numbers the label still prints.
CDRS-R in children, not a grown-up scale
Pediatric depression used a different yardstick. Two eight- to nine-week placebo-controlled trials randomized 315 outpatients - 170 children aged 8 to under 13, 145 adolescents 13 to 18 - on 20 mg daily. Fluoxetine beat placebo on the Childhood Depression Rating Scale-Revised total score in each study on its own. Subgroup cuts did not scream a sex or age split on that scale.
Approval in pediatric major depression starts at age 8. That is a short list among antidepressants, and it is why this molecule still appears in rooms where many siblings do not. It is also why the boxed suicidality language and the trial benefit have to sit in the same sentence. Benefit on CDRS-R does not cancel the need to watch mood and behavior in the first weeks. The watch plan belongs on the safety card. The score belongs here.
Relapse after the open-label stretch
Acute rooms answer 'did the scale move.' Maintenance rooms answer 'did the gain hold.' One study took outpatients who had responded after 12 open weeks on 20 mg - modified HAMD-17 of 7 or less for the last three weeks, no longer meeting major-depression criteria - then randomized 298 of them to stay on 20 mg or switch to placebo. At 38 weeks of double-blind time (50 weeks total), relapse was lower on fluoxetine. Relapse meant two weeks of meeting the diagnosis again, or a modified HAMD-17 of 14 or more for three weeks.
A second maintenance design responded people for three straight weeks after 13 open weeks on 20 mg, then randomized them to daily 20 mg, a 90 mg once-weekly delayed-release capsule, or placebo. Daily 20 mg held a longer time to relapse than placebo across 25 weeks. File that as evidence that staying on the dose that worked beats stopping because you feel fine in month three. It is not a command to stay forever. Duration is a clinical decision. The relapse curves are why 'I feel well, so the trial is over' is a weak review.
Two OCD studies, one messy dose curve
OCD is where reviewers who only read depression blogs go quiet. The rooms were longer and the milligrams were fixed.
Two 13-week multicenter studies enrolled adults with moderate to severe OCD. Mean baseline Yale-Brown Obsessive Compulsive Scale totals sat between 22 and 26. Patients took fixed morning doses of 20, 40, or 60 mg, or placebo. In Study 1, fluoxetine cut Y-BOCS by about 4 to 6 points against a 1-point placebo drop. In Study 2, the drug cut about 4 to 9 points against the same 1-point placebo drop. Study 1 showed no dose-response. Study 2 did, with the two higher arms looking better on the numbers.
That split is why a responsible review does not shout 'OCD always needs 60.' The label still starts adults at 20 mg in the morning, allows a rise after several weeks, names 20 to 60 mg as the usual range, and notes that open work tolerated up to 80. Underdosing and quitting at week three remain the common fumbles. Cognitive behavioral therapy still does heavy lifting. The drug is first-line pharmacotherapy, not a solo cure, and the wait is often longer than the depression wait. Practical titration lives on the weeks-and-taper card.
CGI percentages and the pediatric CY-BOCS arm
| CGI (pooled OCD completers) | Placebo | 20 mg | 40 mg | 60 mg |
|---|---|---|---|---|
| Much or very much improved | 11% | 36% | 39% | 47% |
| No change | 64% | 41% | 33% | 29% |
| Worse | 8% | 0% | 0% | 0% |
Pooled completers from the two adult OCD studies, scored on Clinical Global Impression improvement, are the cleanest 'review' table the label prints. Much improved or very much improved: 11 percent on placebo, 36 percent on 20 mg, 39 percent on 40 mg, 47 percent on 60 mg. Worse: 8 percent on placebo, zero on every fluoxetine arm. No change still sat at 41 percent even on 20 mg. That is a real drug and a large group who barely moved. Both facts belong in the same paragraph.
The pediatric OCD trial randomized 103 patients - 75 children 7 to under 13, 28 adolescents 13 to under 18 - for 13 weeks. They started at 10 mg for two weeks, 20 mg for two weeks, then 20 to 60 mg by response and tolerability. Fluoxetine beat placebo on the Children's Yale-Brown scale. Approval for OCD in children starts at age 7. If a review pretends pediatric OCD is folklore, strike it. If a review pretends every child on 20 mg is 'much improved,' strike that too.
What the reviews skip on purpose
Bulimia and panic sit on the same label and they are not this page's job. File one line each so nobody thinks the desk hid them. In three bulimia trials, only 60 mg - not 20 mg - beat placebo on binge and vomit counts. Panic starts at 10 mg because early activation can mimic the anxiety the person came in with. Premenstrual dysphoric disorder was sold for a time as Sarafem, same molecule, different paint. Those are real approvals. They are not the HAM-D and Y-BOCS argument this review was hired to have.
Against sertraline or escitalopram, depression efficacy is broadly similar. Fluoxetine's long active metabolite, strong CYP2D6 inhibition, and activating tilt are the fit questions, not a potency crown. A review that crowns a winner from forum stars is not reading section 14. Origin of the 20 mg shelf is in the Lilly long-shot file. The molecule as a single note remains the Prozac 20 mg fact line.